EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dendritic cells enhance tebentafusp-mediated T cell effector responses

Manuel Wiesinger, Anne Petzold, Markus Luber, Philipp Hilgendorf, Andreas Wild, Markus V Heppt, Beatrice Schuler-Thurner, Kilian Schober, Carola Berking, Elias A T Koch iD

Cancer Immunology, Immunotherapy · 14.11.2026 · 75 (11)

DOI: 10.1007/s00262-026-04609-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 14.11.2026. Verfasst von Manuel Wiesinger und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Deutsches Zentrum Immuntherapie (DZI), CCC Erlangen-EMN, Bavarian Cancer Research Center (BZKF), Hautklinik, Uniklinikum E…. Hauptthemen laut MEDLINE: Dendritic Cells, Melanoma, T-Lymphocytes, Uveal Neoplasms. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Erlangen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tebentafusp is the first approved T cell receptor (TCR)-based bispecific therapy and prolongs survival in metastatic uveal melanoma by redirecting T cells against gp100/HLA-A*02:01-positive tumor cells. However, how tebentafusp reshapes immune-cell interactions within the tumor microenvironment remains incompletely understood. Here, using HLA-defined donor T cells, dendritic cells (DCs), and tumor cell models with distinct gp100 and HLA-A*02:01 expression profiles, we identify a DC-dependent mechanism that enhances tebentafusp-mediated T cell activation, cytokine production, and cytotoxicity. Across the tumor cell models, the magnitude of tebentafusp-mediated functional responses was closely associated with gp100 abundance and HLA-A*02:01 surface expression. This DC-dependent enhancement was not explained by conventional antigen presentation or the tested CD80/CD86 pathway and was not further enhanced by PD-1 or CTLA-4 blockade. Notably, following direct co-culture with gp100-positive, HLA-A*02:01-positive tumor cells, HLA-A*02:01-negative DCs displayed surface-bound tebentafusp and subsequently enabled tebentafusp-specific T cell activation despite the HLA mismatch. Transfer required gp100 and HLA-A*02:01 expression as well as direct cell–cell contact, consistent with functional DC cross-dressing. Together, these findings reveal a DC-mediated amplification mechanism that extends tebentafusp activity beyond direct tumor–T cell interactions and may shape immune redirection within the tumor microenvironment. Graphical abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dendritic CellsMelanomaT-LymphocytesUveal NeoplasmsHumansLymphocyte ActivationHLA-A2 AntigenCell Line, Tumorgp100 Melanoma AntigenUveal MelanomaTumor MicroenvironmentCoculture Techniques

Stichwörter der Autor:innen

Dendritic cellsImmTACsImmunotherapyT cellsTebentafuspUveal melanoma

Substanzen

HLA-A2 AntigenHLA-A*02:01 antigengp100 Melanoma Antigen

Autor:innen und Institutionen

  • Department of Dermatology, Deutsches Zentrum Immuntherapie (DZI), CCC Erlangen-EMN, Bavarian Cancer Research Center (BZKF), Hautklinik, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Ulme…
  • Dermpath München, Laboratory for Dermatopathology, Oral Pathology, and Molecular Pathology, 80335, Munich, Germany.
  • Department of Immune Modulation, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany.
  • Department of Medicine 5, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany.
  • Mikrobiologisches Institut-Klinische Mikrobiologie, Immunologie Und Hygiene, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany.
  • FAU Profile Center Immunomedicine, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany.

ORCID-Profile: Elias A T Koch

Förderung

  • Universitätsklinikum Erlangen

Zitieren

APA

Wiesinger, M., Petzold, A., Luber, M., Hilgendorf, P., Wild, A., Heppt, M. V., Schuler-Thurner, B., Schober, K., Berking, C., & Koch, E. A. T. (2026). Dendritic cells enhance tebentafusp-mediated T cell effector responses. Cancer Immunology, Immunotherapy, 75(11). https://doi.org/10.1007/s00262-026-04609-3

Vancouver

Wiesinger M, Petzold A, Luber M, Hilgendorf P, Wild A, Heppt MV, et al. Dendritic cells enhance tebentafusp-mediated T cell effector responses. Cancer Immunology, Immunotherapy. 2026;75(11). doi:10.1007/s00262-026-04609-3

BibTeX
@article{Wiesinger2026,
  author = {Wiesinger, Manuel and Petzold, Anne and Luber, Markus and Hilgendorf, Philipp and Wild, Andreas and Heppt, Markus V and Schuler-Thurner, Beatrice and Schober, Kilian and Berking, Carola and Koch, Elias A T},
  title = {Dendritic cells enhance tebentafusp-mediated T cell effector responses},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  volume = {75},
  number = {11},
  doi = {10.1007/s00262-026-04609-3}
}
Kostenlos starten →